Nordson (NDSN) Q2 2026: Backlog Surges 18% as Semiconductor and Medical Demand Accelerate
Nordson delivered a record-breaking Q2, with all segments contributing to 8% top-line growth and a robust 18% organic backlog expansion, driven by surging demand in semiconductor, electronics, and medical end markets. The ATS segment’s double-digit order momentum, combined with medical normalization and industrial recovery, supports a guidance raise and signals durable customer demand. With a diversified portfolio and disciplined capital allocation, Nordson is positioned for continued compounding growth, though inflation and macro volatility remain key watchpoints.
Summary
- Backlog Expansion Signals Demand Visibility: 18% organic backlog growth reflects broad-based order strength across all segments.
- Semiconductor and Medical Cycles Accelerate: ATS and medical segments both inflect, supporting above-market organic growth.
- Capital Deployment Remains Disciplined: Bolt-on M&A and cash returns executed while maintaining sub-2x leverage.
Business Overview
Nordson is a diversified precision technology manufacturer, specializing in dispensing, coating, and test and inspection systems for industrial, medical, electronics, and advanced technology end markets. The company generates revenue through three primary segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS). Nordson’s business model blends high-margin consumables with engineered systems, leveraging a close-to-the-customer approach and recurring aftermarket demand. The portfolio is increasingly weighted to growth categories, with over half of revenues now from semiconductor, electronics, and medical markets.
Performance Analysis
Nordson delivered an 8% revenue increase for Q2 2026, driven by 7% organic growth and 3% currency tailwind, with all three segments reaching record sales. The company’s EBITDA margin held steady at 32%, underpinned by operating leverage and disciplined SG&A management. Free cash flow conversion again exceeded 100% of net income, enabling simultaneous investment and shareholder returns.
Segment performance was broad-based: IPS grew 10% (5% organic), led by industrial coating, polymer processing, and precision agriculture; MFS rose 5% (8% organic), as medical demand normalized; ATS surged 10% (8% organic), with strength in electronics dispense and semiconductor applications. Notably, ATS posted a record 27% EBITDA margin, reflecting past footprint optimization and the NBS Next framework.
- Backlog Momentum: Backlog rose 18% organically, with ATS contributing double-digit order growth and all segments participating.
- Margin Dynamics: Incremental EBITDA conversion improved to 31% but remains below historical levels due to inflationary pressures and product mix.
- Cash Deployment: $170 million in free cash flow funded $46 million in dividends, $43 million in share buybacks, and $10 million in CapEx, while net debt fell to 1.9x EBITDA.
Order entry accelerated late in the quarter and into Q3, giving management confidence to raise both sales and EPS guidance for the year. While inflation and input costs pressured incrementals, margin discipline and portfolio mix helped maintain best-in-class profitability.
Executive Commentary
"Order entry momentum continued throughout the quarter with accelerated activity in the last couple of months, driving up backlog 18% organically compared to the prior year."
Sundaram Nagarajan, President and Chief Executive Officer
"All three of our segments achieved record second quarter sales and our ATS segment achieved an all-time record quarterly performance. Our cash conversion remains strong, allowing us to strategically deploy capital to sustainably grow the franchise and return value to shareholders."
Dan Hopgood, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Semiconductor and Electronics Tailwind
ATS, advanced technology solutions, is now over 50% semiconductor-exposed and delivered double-digit order growth, benefiting from AI infrastructure buildout, panel-level packaging, and optical fiber content. The segment’s diversification beyond dispense into test and inspection, plus a broadened customer base, reduces cyclicality and positions Nordson to capture a multi-year technology upgrade cycle.
2. Medical Normalization and Regulatory Navigation
MFS, medical and fluid solutions, returned to 8% organic growth, with order entry and backlog supporting normalized 6-8% targets. Management noted a temporary margin headwind from a regulatory-driven material change in interventional products, but expects this to become a margin opportunity as the year progresses. The long-term medical thesis—aging demographics, chronic disease, and minimally invasive technology—remains intact.
3. Industrial Recovery and Precision Ag Expansion
IPS, industrial precision solutions, posted 5% organic growth, with improvements in coating, polymer processing, and adhesives. The Capstan AG acquisition expands Nordson’s North American precision agriculture footprint, consolidating operations and targeting mid-tier OEMs. Management sees efficiency and material savings as a differentiator for customers facing inflation and supply constraints.
4. Capital Allocation and M&A Discipline
Nordson maintains a balanced capital deployment strategy, blending organic investment, bolt-on M&A, and shareholder returns. The Capstan AG deal, at 9x EBITDA, exemplifies disciplined bolt-on execution. Management signaled a robust M&A pipeline, with a focus on medical, test and inspection, and technology adjacencies, while maintaining strict strategic and financial criteria.
5. Portfolio Diversification and End Market Balance
With over half the portfolio now in growth end markets, Nordson is less exposed to GDP-linked cyclicality. The remaining segments provide steady cash flow, while growth categories drive compounding. This mix supports resilience and optionality amid macro uncertainty.
Key Considerations
Nordson’s Q2 results reflect a company benefiting from both cyclical and secular growth drivers, but also navigating inflationary pressures and dynamic order patterns. The company’s operational discipline, high recurring revenue, and diversified portfolio underpin its compounding thesis, yet investors should stay alert to several evolving dynamics:
Key Considerations:
- Order Book Visibility: 18% backlog growth and broad-based order entry provide strong near-term revenue visibility, particularly in ATS and medical.
- Margin Management: Incremental margins remain below historical conversion rates due to inflation, but management is prioritizing growth and maintaining profitability rather than expanding margins in this environment.
- Inflation and Input Costs: Persistent inflation in components, resins, and tariffs is a headwind, mitigated by selective pricing and cost actions across all segments.
- Capital Flexibility: Sub-2x leverage and robust free cash flow enable continued M&A and shareholder returns without sacrificing balance sheet strength.
- Cycle Positioning: Management believes ATS is in the early stages of a semiconductor upcycle, with multiple new technology applications supporting multi-year demand.
Risks
Macro volatility remains the primary risk, with management flagging potential raw material shortages or broader economic pullback as possible drivers of order deceleration. Inflationary headwinds persist, especially in IPS, where input costs and tariffs are impacting incremental margins. Medical margin recovery depends on timely resolution of regulatory-driven material changes, and any delay could pressure segment profitability. Finally, the M&A pipeline, while active, is subject to market valuations and competitive bids, which could limit inorganic growth if discipline is maintained.
Forward Outlook
For Q3 2026, Nordson guided to:
- Sales of $760 million to $790 million
- Adjusted EPS of $2.95 to $3.15 per share
For full-year 2026, management raised guidance:
- Sales of $2.93 billion to $3.01 billion
- Adjusted EPS of $11.30 to $11.80 per share
Management highlighted several factors that shape the outlook:
- Order momentum remains strong across all segments, supporting confidence in the midpoint of guidance.
- Foreign exchange impact will be neutral in the second half, after a first-half tailwind.
- M&A and divestiture net impact is a slight negative to second-half growth, but organic trends are robust.
- Guidance assumes current demand trends persist, with downside risk only if macro conditions drive a meaningful order pullback.
Takeaways
Nordson’s diversified model and focus on growth end markets are driving record results and backlog, positioning the company for continued compounding even amid inflation and macro uncertainty.
- Backlog Expansion: 18% organic backlog growth signals strong demand visibility, especially in ATS and medical, supporting raised guidance and multi-quarter revenue confidence.
- Margin Discipline Amid Inflation: While incrementals are below historical levels, Nordson is maintaining best-in-class margins through pricing, cost control, and portfolio mix, prioritizing growth over margin expansion in the current environment.
- Strategic Capital Allocation: Robust free cash flow funds organic investment, disciplined bolt-on M&A, and steady shareholder returns, while sub-2x leverage preserves future flexibility.
- Watch for Macro-Driven Demand Shifts: Investors should monitor order trends, inflation impact, and medical margin recovery as key variables for the second half.
Conclusion
Nordson’s Q2 2026 results confirm its ability to deliver above-market growth and margin discipline across a diversified, innovation-driven portfolio. With backlog surging and all segments inflecting, the company is positioned for sustained compounding, though vigilance on inflation and macro risk is warranted in the back half.
Industry Read-Through
Nordson’s broad-based order strength and backlog expansion provide a positive read-through for industrial technology, semiconductor capital equipment, and medical device suppliers. The company’s commentary on early-stage semiconductor cycle recovery, AI infrastructure buildout, and normalization in medical demand aligns with improving trends across automation and precision manufacturing peers. Persistent inflation and input cost pressures remain a sector-wide challenge, with best-in-class operators maintaining margins through pricing power and operational leverage. Disciplined M&A and capital deployment are increasingly differentiating winners from peers, as balance sheet strength enables strategic flexibility in a still-competitive deal market. Investors should monitor ATS and medical end market order trends as leading indicators for the broader industrial and technology supply chain.